Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-214582 · Präparat HOS-155350
In GEICAM 9805 study alopecia that started during the treatment period and persisted into the follow- up period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage a71852ff17d3bfe0786d840d2ad456aae91e7362323d85ed3ae59996995aa952 · Zeichen 33871–34418 im Abschnitt